Institution
OHSU
Degree
MD
Presentation Type
Poster
Room Location
Smith Memorial Student Union, Room 296/8
Start Date
April 2019
End Date
April 2019
Rights
© Copyright the author(s)
IN COPYRIGHT:
http://rightsstatements.org/vocab/InC/1.0/
This Item is protected by copyright and/or related rights. You are free to use this Item in any way that is permitted by the copyright and related rights legislation that applies to your use. For other uses you need to obtain permission from the rights-holder(s).
DISCLAIMER:
The purpose of this statement is to help the public understand how this Item may be used. When there is a (non-standard) License or contract that governs re-use of the associated Item, this statement only summarizes the effects of some of its terms. It is not a License, and should not be used to license your Work. To license your own Work, use a License offered at https://creativecommons.org/
Persistent Identifier
https://archives.pdx.edu/ds/psu/30962
Abstract
Introduction: Atopic dermatitis (AD) is the most common chronic inflammatory skin disease in the United States. AD is associated with reduced quality of life and substantial financial costs, making it burdensome at an individual and population level. Disease severity outcome measures are validated tools to assess severity and therapeutic response. Recent consensus statements have identified gold-standard outcome measures for AD in clinical trials, but further work is needed evaluating outcome measures feasible for clinical practice.
Objective: To investigate the validity and feasibility of the product of investigator global assessment and body surface area (IGA x BSA) as an outcome measure for AD in the clinical setting.
Methods and Results: Retrospective chart review of patients with AD seen in an outpatient dermatology clinic at Oregon Health & Science University from 2015-2018 with recorded BSA and IGA revealed 246 patients comprising 682 clinic visits. We observed strong and statistically significant correlations between IGA x BSA and the gold-standard measurement for clinical signs in clinical trials, the Eczema Area and Severity Index (r=0.9105, p <0.0001, n=19). IGA x BSA also showed strong correlations with the average daily pruritus numerical rating scale (r=0.7108, p <0.0001, n=177) and the patient global assessment (r=0.7389, p <0.0001, n=170).
Conclusions: IGA x BSA is a valid and feasible outcome measure for AD which aligns with patient-reported disease severity and may be used in real-world clinical practice.
Included in
Dermatology Commons, Other Public Health Commons, Skin and Connective Tissue Diseases Commons
Validity of an atopic dermatitis outcome measure for real-world clinical practice
Smith Memorial Student Union, Room 296/8
Introduction: Atopic dermatitis (AD) is the most common chronic inflammatory skin disease in the United States. AD is associated with reduced quality of life and substantial financial costs, making it burdensome at an individual and population level. Disease severity outcome measures are validated tools to assess severity and therapeutic response. Recent consensus statements have identified gold-standard outcome measures for AD in clinical trials, but further work is needed evaluating outcome measures feasible for clinical practice.
Objective: To investigate the validity and feasibility of the product of investigator global assessment and body surface area (IGA x BSA) as an outcome measure for AD in the clinical setting.
Methods and Results: Retrospective chart review of patients with AD seen in an outpatient dermatology clinic at Oregon Health & Science University from 2015-2018 with recorded BSA and IGA revealed 246 patients comprising 682 clinic visits. We observed strong and statistically significant correlations between IGA x BSA and the gold-standard measurement for clinical signs in clinical trials, the Eczema Area and Severity Index (r=0.9105, p <0.0001, n=19). IGA x BSA also showed strong correlations with the average daily pruritus numerical rating scale (r=0.7108, p <0.0001, n=177) and the patient global assessment (r=0.7389, p <0.0001, n=170).
Conclusions: IGA x BSA is a valid and feasible outcome measure for AD which aligns with patient-reported disease severity and may be used in real-world clinical practice.